European Archives - Page 973 of 1021 - European Medical Journal

EMJ

ESMO 2014: Tumour evolution and precision medicine

At ESMO 2014, Prof Charles Swanton (London Research Institute and UCL, London, UK) discusses how understanding the genetic changes in tumour evolution…

EMJ

ESMO 2014: Tumour evolution and proactive clinical management

At ESMO 2014, Prof Charles Swanton (London Research Institute and UCL, London, UK) discusses how we can begin to anticipate tumour evolutionary…

Editor’s Pick: Paradigm Shift in the Management of Gynaecological Cancers

In this review we highlight novel aspects of diagnostic imaging in gynaecological cancers, the paradigm shift in the surgical management of certain…

Field Cancerisation of the Upper Aerodigestive Tract: Screening for Second Primary Cancers of the Oesophagus in Cancer Survivors

Tobacco, alcohol, and betel quid are the main causes of squamous cell cancers of the upper aerodigestive tract. These substances can cause multifocal…

Perspectives in Surgery of Oligometastatic Non-Small-Cell Lung Cancer

20-50% of patients with newly diagnosed non-small-cell lung cancer (NSCLC) have synchronous metastases. This dramatically affects survival and…

Symptoms and Quality of Life in Gastroenteropancreatic Neuroendocrine Tumours

Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) have the ability to induce symptoms either by their direct mass effect on local tissues…

Recent Advances in Definitive Radiotherapy for Prostate Cancer

Definitive radiation therapy is a well-recognised curative treatment option for localised prostate cancer. A suitable technique, dose, target volume…

Development of Drugs Targeting the PI3K Signalling Pathway in Leukaemias and Lymphomas

The phosphoinositide 3-kinase (PI3K) family of signalling enzymes play a key role in the transduction of signals from activated cell surface receptors…

Alloimmune Thrombocytopaenic Disorders: A Review

Alloimmune thrombocytopaenia (AIT) is caused by alloantibodies against specific platelet glycoproteins. Alloimmune thrombocytopaenic disorders include…

Multiple Myeloma and Renal Failure

Renal failure (RF) occurs in approximately 20-30% of multiple myeloma (MM) patients at diagnosis and in more than 50% of patients with advanced disease.